Authors:
Address: Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
Journal:

Publication:

abstract

Francisella tularensis, a category A bioterrorism agent, is a highly infectious organism that is passed on via skin contact and inhalation routes. A live attenuated vaccine strain (LVS) has been developed, but it has not been licensed for public use by the FDA due to safety concerns. Thus, there exists a need for a safer and improved vaccine. In this study, we have constructed a replication-incompetent adenovirus, Ad/opt-Tul4, carrying a codon-optimized gene for expression of a membrane protein, Tul4, of F. tularensis LVS. Its ability to protect against lethal challenge and its immunogenicity were evaluated in a murine model. An intramuscular injection of a single dose (1 × 10(7) PFU) of Ad/opt-Tul4 elicited a robust Tul4-specific antibody response. Assays suggest a Th1-driven response. A single dose elicited 20% protection against challenge with 100 × 50% lethal dose (LD(50)) F. tularensis LVS; two additional booster shots resulted in 60% protection. In comparison, three doses of 5 μg recombinant Tul4 protein did not elicit significant protection against challenge. Therefore, the Ad/opt-Tul4 vaccine was more effective than the protein vaccine, and protection was dose dependent. Compared to LVS, the protection rate is lower, but an adenovirus-vectored vaccine may be more attractive due to its enhanced safety profile and mucosal route of delivery. Furthermore, simple genetic modification of the vaccine may potentially produce antibodies Protective against a fully virulent strain of F. tularensis. Our data support the development and further research of an adenovirus-vectored vaccine against Tul4 of F. tularensis LVS.

Related Articles
A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.
Infect Immun. 2010
A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.
Jia Q, Lee BY, Bowen R, Dillon BJ, Som SM, Horwitz MA. Infect Immun. 2010 Oct; 78(10):4341-55. Epub 2010 Jul 19.
Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis.
Vaccine. 2007
Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis.
KuoLee R, Harris G, Conlan JW, Chen W. Vaccine. 2007 May 10; 25(19):3781-91. Epub 2007 Feb 26.
Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia.
Vaccine. 2011
Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia.
Hickey AJ, Hazlett KR, Kirimanjeswara GS, Metzger DW. Vaccine. 2011 Sep 16; 29(40):6941-7. Epub 2011 Jul 29.
Review Vaccination strategies for Francisella tularensis.
Adv Drug Deliv Rev. 2005
Review Vaccination strategies for Francisella tularensis.
Isherwood KE, Titball RW, Davies DH, Felgner PL, Morrow WJ. Adv Drug Deliv Rev. 2005 Jun 17; 57(9):1403-14.
Review Nature of protective immunity to Francisella tularensis.
Rev Infect Dis. 1989
Review Nature of protective immunity to Francisella tularensis.
Tärnvik A. Rev Infect Dis. 1989 May-Jun; 11(3):440-51.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster